When Will Retatrutide Be FDA Approved? 2026 Timeline
Key takeaways
- Not FDA approved as of June 2026; no application filed yet.
- Eli Lilly expected to file before end of 2026.
- Realistic FDA decision: late 2027-2028; launch after that.
- No legitimate compounded retatrutide exists – avoid gray-market sellers.
Where it stands now
The pivotal Phase 3 obesity trial, TRIUMPH-1 (2,339 patients), has read out with strong results — about 24–28% average weight loss at the top dose and 45.3% of patients losing at least 30% of body weight. That gives Lilly the core dataset needed to file a New Drug Application (NDA). Additional trials (diabetes, cardiovascular) are still maturing.
The realistic timeline
- NDA filing: expected by end of 2026.
- FDA review: roughly 10–12 months standard, or ~6 months with priority review.
- Decision: realistically late 2027 (priority) to 2028 (standard).
- Launch: typically 1–3 months after approval, subject to manufacturing scale-up.
What to do in the meantime
If you’re preparing, the smartest move is the habit that carries into any GLP-1 drug: lock in a high-protein eating pattern now. It preserves muscle, builds the routine, and makes the eventual transition smoother.
FAQ
Is retatrutide FDA approved yet?
No. As of June 2026 it is investigational. An FDA filing is expected by end of 2026, with a decision realistically in late 2027 to 2028.
Can I get retatrutide in 2026?
Not legally by prescription. It has not been approved and no legitimate compounded version exists.
Will retatrutide be covered by insurance?
Too early to say — coverage is set after approval and launch pricing, likely 2028 at the earliest.
What has to happen before approval
Approval isn’t a single switch. Eli Lilly first compiles the full safety and efficacy dataset, then files a New Drug Application (NDA). The FDA decides whether to accept the filing, runs its review (often with an advisory committee for a major new drug), inspects manufacturing, and finally issues a decision. Each step has its own clock, which is why “the trial worked” and “you can fill a prescription” are years apart.
Best, base, and worst case
| Scenario | Filing | FDA decision | Earliest fill |
|---|---|---|---|
| Best case | Q3 2026, priority review | Mid 2027 | Late 2027 |
| Base case | Q4 2026, standard review | Late 2027 – 2028 | 2028 |
| Slower | 2027 (more data requested) | 2028 – 2029 | 2029 |
How this compares to Wegovy and Zepbound
It’s a useful reality check: semaglutide and tirzepatide each took years from pivotal data to a weight-loss approval and launch, and both then hit supply shortages once demand exploded. Retatrutide will likely follow the same arc, which is another reason not to put life on hold waiting for it.
What it might cost at launch
No price exists yet. As a brand-new branded drug, retatrutide would most likely launch near the list prices of today’s GLP-1 drugs (roughly $1,000-$1,350 a month before insurance or savings programs), with coverage widening gradually over the first year or two. Anyone quoting a cheap “retatrutide price” today is selling something that isn’t the approved drug.
The Retatrutide 2026 series
The nutrition side most drug guides skip
We are a food site, so here is what the drug-only sites leave out: retatrutide and today’s approved GLP-1 drugs works by shrinking appetite, and that creates a real nutritional risk. When you eat far less, you do not just lose fat – you can lose muscle and fall short on protein, fiber, and key vitamins and minerals. The fix is not eating more; it is making every bite count.
The four risks to manage (and the food fix)
| Nutrition risk | Why it happens | The food fix |
|---|---|---|
| Muscle & protein loss | Rapid weight loss plus too little protein – up to a third of lost weight can be lean muscle. | 1.2-1.6 g protein per kg body weight daily; anchor every meal and snack with protein. |
| Low micronutrients | Eating far less total food shrinks intake of iron, B12, calcium, vitamin D, potassium and magnesium. | Nutrient-dense picks: eggs, salmon/sardines, Greek yogurt, leafy greens, beans, nuts and seeds, fortified foods. |
| Constipation | Slowed digestion plus less food and fiber. | Fiber-rich vegetables and fruit you can tolerate; steady fluids; move daily. |
| Dehydration & low energy | Reduced intake and GI fluid losses during dose changes. | Sip fluids and electrolytes through the day; never skip food entirely. |
What to actually eat on retatrutide and today’s approved GLP-1 drugs
- Protein at every meal and snack: eggs, chicken, fish, Greek yogurt, cottage cheese, tofu, beans, or a protein shake. When you can only finish a few bites, make them protein.
- Nutrient-dense, smaller-volume foods: salmon and sardines (omega-3, vitamin D, B12), eggs, dairy, leafy greens, beans and lentils, nuts and seeds, berries.
- Easy formats for nausea days: protein smoothies (protein powder + fruit + spinach), broth-based soups, yogurt.
- Hydration and fiber: water and electrolytes through the day, plus tolerable high-fiber vegetables and fruit to keep things moving.
If your appetite is so low that you are eating very little, a daily multivitamin can backstop the gaps – ask your prescribing clinician. The goal across the board: protect muscle and stay nourished while the medication does its job.
The simplest way to hit these numbers while your appetite is unpredictable is pre-portioned, macro-labeled meal delivery built for exactly this.
See our tested GLP-1 meal delivery picks →
Or browse Best High-Protein Meal Delivery
Sources & references
- Eli Lilly. Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Lilly press release (2026).
- Retatrutide: what is it and is it FDA approved? Drugs.com.
- Retatrutide – overview, mechanism, trial history. Wikipedia.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. New England Journal of Medicine (2023).
Related reading
Figures reflect Eli Lilly topline disclosures and peer-reviewed trial publications as of June 25, 2026. Retatrutide remains investigational; we will update on FDA action. Not medical advice.